Association of Serum Antioxidant Vitamins and Carotenoids With Incident Alzheimer Disease and All-Cause Dementia Among US Adults

May A. Beydoun, PhD, MPH, Hind A. Beydoun, PhD, MPH, Marie T. Fanelli-Kuczmaszki, PhD, et al.

Cite as: Neurology® 2022;98:e2150-e2162. doi:10.1212/WNL.0000000000200289

Study Question
Do serum vitamins A, C, and E and total and individual serum carotenoids associate individually or interactively with incident Alzheimer disease (AD) and all-cause dementia?

What Is Known and What This Paper Adds
Serum antioxidant vitamins and carotenoids may protect against neurodegeneration with age. No nationally representative study to date has investigated whether serum levels of carotenoids in general may interact with each other and with vitamins A, C, or E in relation to incidence rates of AD or all-cause dementia. This study provides Class II evidence that incident all-cause dementia was inversely associated with serum lutein+zeaxanthin and β-cryptoxanthin levels.

Methods
Using data from the third National Health and Nutrition Examination Surveys (1988–1994), linked with Centers for Medicare & Medicaid Services follow-up data, we tested associations and interactions of serum vitamins A, C, and E and total and individual serum carotenoids and interactions with incident AD and all-cause dementia. Cox proportional hazards regression models were conducted.

Results and Study Limitations
After ≤26 years follow-up (mean 16–17 years, n = 7,283 participants age 45–90 years at baseline), serum lutein + zeaxanthin was associated with reduced risk of all-cause dementia (65+ age group), even in the lifestyle-adjusted model (per SD, hazard ratio [HR] 0.93, 95% CI 0.87–0.99; p = 0.037), although attenuated in comparison with a socioeconomic status (SES)–adjusted model (HR 0.92, 95% CI 0.86–0.93; p = 0.013) (Table). An inverse relationship was detected between serum β-cryptoxanthin (per SD increase) and all-cause dementia (45+ and 65+) for age- and sex-adjusted models (HR 0.86, 95% CI 0.80–0.93; p < 0.001 for 45+; HR 0.86, 95% CI 0.80–0.93; p = 0.001 for 65+), a relationship remaining strong in SES-adjusted models (HR 0.89, 95% CI 0.82–0.96; p = 0.006 for 45+; HR 0.88, 95% CI 0.81–0.96; p = 0.007 for 65+), but attenuated in subsequent models (Table). Some antagonistic interactions were detected among carotenoids and between carotenoids and antioxidant vitamins in relation to both outcomes. Our study has several limitations, including worse overall health and access to health care among those diagnosed earlier, baseline exclusion of dementia or cognitive impairment cases based on a household screener, and the possible confounding effects of medications and other nutrients on the main findings.

Study Funding and Competing Interests
This work was supported partly by the Intramural Research Program of the NIH, National Institute on Aging, NIH project number AG000513. The authors report no competing interests. Go to Neurology.org/N for full disclosures.

Table

<table>
<thead>
<tr>
<th>Lutein + zeaxanthin</th>
<th>Age 45+ y (n = 7,257)</th>
<th>Age 65+ y (n = 3,593)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Model 1</td>
<td>−0.084 ± 0.033; p = 0.016</td>
<td>−0.088 ± 0.034; p = 0.013</td>
</tr>
<tr>
<td>Model 2</td>
<td>−0.061 ± 0.032; p = 0.063</td>
<td>−0.071 ± 0.033; p = 0.037</td>
</tr>
<tr>
<td>Model 3</td>
<td>−0.061 ± 0.041; p = 0.14</td>
<td>−0.083 ± 0.044; p = 0.062</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>β-cryptoxanthin</th>
<th>Age 45+ y (n = 7,257)</th>
<th>Age 65+ y (n = 3,593)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Model 1</td>
<td>−0.115 ± 0.040; p = 0.006</td>
<td>−0.126 ± 0.045; p = 0.007</td>
</tr>
<tr>
<td>Model 2</td>
<td>−0.070 ± 0.041; p = 0.092</td>
<td>−0.076 ± 0.047; p = 0.11</td>
</tr>
<tr>
<td>Model 3</td>
<td>−0.072 ± 0.047; p = 0.13</td>
<td>−0.074 ± 0.054; p = 0.18</td>
</tr>
</tbody>
</table>

β = loge (HR), SE.

*Model 1: demographics/socioeconomic factors; model 2: model 1+ lifestyle-related factors; model 3: model 2+health-related factors.
Association of Serum Antioxidant Vitamins and Carotenoids With Incident Alzheimer Disease and All-Cause Dementia Among US Adults
May A. Beydoun, Hind A. Beydoun, Marie T. Fanelli-Kuczkmarski, et al.
Neurology 2022;98:e2150-e2162 Published Online before print May 4, 2022
DOI 10.1212/WNL.0000000000200289

This information is current as of May 4, 2022

Updated Information & Services
including high resolution figures, can be found at:
http://n.neurology.org/content/98/21/e2150.full

References
This article cites 38 articles, 5 of which you can access for free at:
http://n.neurology.org/content/98/21/e2150.full#ref-list-1

Citations
This article has been cited by 1 HighWire-hosted articles:
http://n.neurology.org/content/98/21/e2150.full##otherarticles

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
All Cognitive Disorders/Dementia
http://n.neurology.org/cgi/collection/all_cognitive_disorders_dementia
Alzheimer's disease
http://n.neurology.org/cgi/collection/alzheimers_disease
Class II
http://n.neurology.org/cgi/collection/class_ii
Cohort studies
http://n.neurology.org/cgi/collection/cohort_studies
Incidence studies
http://n.neurology.org/cgi/collection/incidence_studies
Nutritional
http://n.neurology.org/cgi/collection/nutritional

Permissions & Licensing
Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints
Information about ordering reprints can be found online:
http://n.neurology.org/subscribers/advertise